Strategic partner 3SBio and Alexandria Venture Investments have both contributed to a $50m round raised by Verseau that was disclosed as it emerged from stealth.
US-based cancer immunotherapy developer Verseau Therapeutics launched with $50m in funding yesterday from investors including biotechnology producer 3SBio and life sciences real estate investment trust Alexandria Real Estate Equities.
The round also featured 20/20 HealthCare Partners, Highlight Capital, Yonghua Capital, InHarv Partners and Mark Foundation for Cancer Research, while Alexandra Real Estate Equities participated through its Alexandria Venture Investments unit.
Founded in 2017, Verseau is working on immunotherapies that reprogram macrophages – large cells that are found at sites of…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
